Posted by Michael Wonder on 15 Feb 2023
Vutrisiran for the treatment of patients with hereditary transthyretin-related amyloidosis
15 February 2023 - NICE has published final draft guidance on the use of vutrisiran for the treatment of adults with treating hereditary transthyretin-related amyloidosis.
Vutrisiran is recommended as an option for the treatment of adults with treating hereditary transthyretin-related amyloidosis with stage 1 or stage 2 polyneuropathy.
It is only recommended if Alnylam Pharmaceuticals provides vutrisiran according to the commercial arrangement.
